Moleculin Biotech, Inc. 8-K

What Happened
Moleculin Biotech, Inc. (MBRX) filed a Form 8-K (Item 7.01) reporting that an abstract featuring pooled cardiac safety data for its lead drug candidate Annamycin (also called L-Annamycin or naxtarubicin) has been accepted for a poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO meeting runs May 29–June 2, 2026, in Chicago, Illinois. The company attached a press release (dated May 21, 2026) and the abstract to the filing as exhibits.

Key Details

• Filing: Form 8-K (Item 7.01) filed May 22, 2026 (press release dated May 21, 2026).
• Event: Abstract on pooled cardiac safety data for Annamycin accepted for poster presentation at ASCO 2026.
• Meeting: ASCO Annual Meeting, May 29–June 2, 2026, Chicago, IL.
• Exhibits: Press release and abstract attached to the 8-K (Exhibits 99.1 and 99.2).

Why It Matters
Acceptance of a poster at ASCO signals that Moleculin is progressing its clinical data disclosure for Annamycin, with specific focus on cardiac safety — a key concern for anthracycline-like cancer drugs. For investors, this is a transparency and visibility event rather than a financial update: it may increase scientific and clinical awareness of the program and provide data points that analysts or partners could evaluate as the clinical program advances. The filing does not report new financial results or regulatory approvals.